^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral entry inhibitor

    Related drugs:
    3d
    Efficacy of Self-Formulated Ergan Tang on Paroxysmal Atrial Fibrillation in Elderly Patients with Qi-Yin Deficiency: Impact on Inflammatory Marker Levels. (PubMed, J Inflamm Res)
    The self-formulated Ergan Tang demonstrates efficacy in alleviating AF burden, reducing inflammatory factor levels, and improving TCM symptom scores among elderly patients with paroxysmal AF characterized by qi-yin deficiency. Notably, its efficacy is comparable to that of amiodarone.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    10d
    Lubricating Effectiveness of Carragelose Eye Drops in Patients Affected by Mild to Moderate Dry Eye (clinicaltrials.gov)
    P=N/A, N=30, Completed, Marinomed Biotech AG | Recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024
    Trial completion • Trial completion date
    10d
    Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone (clinicaltrials.gov)
    P1, N=63, Recruiting, University of Chicago | Trial primary completion date: Nov 2024 --> Jun 2025
    Trial primary completion date • Surgery
    28d
    MARCH: Study of VIR-2218, VIR-3434, And/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P2, N=244, Active, not recruiting, Vir Biotechnology, Inc. | Recruiting --> Active, not recruiting | N=415 --> 244
    Enrollment closed • Enrollment change
    28d
    A Phase 2 Study of Leronlimab in Combination with TAS-102 + Bevacizumab in Previously Treated Participants with MCRC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, CytoDyn, Inc.
    New P2 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Vyrologix (leronlimab)
    29d
    The Tatelo Plus Study (clinicaltrials.gov)
    P1/2, N=41, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    29d
    Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study (clinicaltrials.gov)
    P3, N=274, Recruiting, Ansun Biopharma, Inc. | Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    1m
    Early-Amio: Early Amiodarone in Shockable Cardiac Arrest (clinicaltrials.gov)
    P3, N=585, Not yet recruiting, Oregon Health and Science University
    New P3 trial
    2ms
    Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (clinicaltrials.gov)
    P=N/A, N=51, Not yet recruiting, IRCCS Ospedale San Raffaele
    New trial
    2ms
    Comparative study of the protective effects of coenzyme Q10 and cinnamon extract on possible kidney damage and dysfunction of amiodarone in rats. (PubMed, Clin Exp Nephrol)
    Although CoQ10, CE, and CoCE effectively prevent amiodarone-induced oxidative and inflammatory nephrotoxicity, CoCE appears to be superior.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • KIM1 (Kidney injury molecule 1) • IL1B (Interleukin 1, beta) • CAT (Catalase)
    2ms
    Diacerein ameliorates amiodarone-induced pulmonary fibrosis via targeting the TGFβ1/α-SMA/Smad3 pathway. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Moreover, DIA reduced TNF-α and caspase-3 protein expression. DIA attenuated AMD-induced pulmonary fibrosis via alleviating the TGF1/α-SMA/Smad3 pathway, reducing STAT-3 activation, and combating oxidative stress and inflammation in addition to promoting autophagy and abrogating apoptosis.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • SMAD3 (SMAD Family Member 3)
    2ms
    A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia (clinicaltrials.gov)
    P2, N=74, Completed, Huahui Health | Active, not recruiting --> Completed | Phase classification: P2a --> P2 | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial completion • Phase classification • Trial primary completion date
    2ms
    A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection (clinicaltrials.gov)
    P2, N=80, Enrolling by invitation, Huahui Health | Recruiting --> Enrolling by invitation | Phase classification: P2b --> P2
    Enrollment status • Phase classification
    3ms
    Uni-Koeln-4370: SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation (clinicaltrials.gov)
    P1/2, N=45, Terminated, University of Cologne | Completed --> Terminated; Change in viral variant epidemiology
    Trial termination
    3ms
    The possible effects of chronic administration of amiodarone hydrochloride on the seminiferous tubules of adult male albino rats: histological and biochemical study. (PubMed, Ultrastruct Pathol)
    Testes specimens were examined to assess the morphological changes and the level of expression of caspase-3 apoptotic marker. The results indicated that; amiodarone hydrochloride could induce a dose-dependent toxicity, causing oxidative stress, inflammation, cellular degeneration, deposition of collagen and enhanced apoptosis in the seminiferous tubules.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3)
    3ms
    A multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Nifekalan hydrochloride injection and Amiodarone hydrochloride injection in the treatment of recent-onset fibrillation/atrial flutter (ChiCTR2400087991)
    P=N/A, N=240, Completed, Fuwai Hospital, Chinese Academy of Medical Sciences; Fuwai Hospital, Chinese Academy of Medical Sciences
    New trial
    4ms
    Biphenylsulfonamides as effective MMP-2 inhibitors with promising antileukemic efficacy: Synthesis, in vitro biological evaluation, molecular docking, and MD simulation analysis. (PubMed, Drug Dev Res)
    Apart from that, the MD simulation study also disclosed stable binding interactions of DH-18 and MMP-2 along with crucial interactions with active site amino acid residues namely His120, Glu121, His124, His130, Pro140, and Tyr142. In a nutshell, this study highlighted the importance of biphenylsulfonamide-based novel and promising MMP-2 inhibitors to open up a new avenue for potential therapy against CML.
    Preclinical • Journal
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    Vyrologix (leronlimab)
    4ms
    L-Carnitine Ameliorates Amiodarone-Mediated Alveolar Damage: Oxidative Stress Parameters, Inflammatory Markers, Histological and Ultrastructural Insights. (PubMed, Pharmaceuticals (Basel))
    Tumor necrosis factor alpha levels were significantly reduced upon L-carnitine exposure. These results suggest that L-carnitine can be used to treat amiodarone-induced pulmonary dysfunction.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CAT (Catalase)
    4ms
    A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission (clinicaltrials.gov)
    P2, N=48, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    4ms
    TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals (clinicaltrials.gov)
    P1/2, N=90, Active, not recruiting, TaiMed Biologics Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Nov 2024 | Trial primary completion date: Apr 2024 --> Nov 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    4ms
    Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    4ms
    Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis (clinicaltrials.gov)
    P=N/A, N=106, Not yet recruiting, Chinese Academy of Medical Sciences, Fuwai Hospital
    New trial
    4ms
    A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=64, Suspended, Arisan Therapeutics, Inc. | Trial completion date: Oct 2023 --> Apr 2025 | Recruiting --> Suspended | Trial primary completion date: Jul 2023 --> Jan 2025
    Trial completion date • Trial suspension • Trial primary completion date
    5ms
    Safety Study of SLV213 for the Treatment of COVID-19. (clinicaltrials.gov)
    P1, N=16, Terminated, National Institute of Allergy and Infectious Diseases (NIAID) | N=36 --> 16 | Suspended --> Terminated; DMID unanimously arrived at a recommendation to terminate the study after study met cohort halting criteria.
    Enrollment change • Trial termination
    5ms
    Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1 (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID)
    New P1 trial • Combination therapy
    5ms
    BRIGHTE : Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients (clinicaltrials.gov)
    P3, N=371, Active, not recruiting, ViiV Healthcare | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    5ms
    The Tatelo Plus Study (clinicaltrials.gov)
    P1/2, N=41, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID)
    New P1/2 trial
    |
    CD4 (CD4 Molecule)
    5ms
    Safety Study of SLV213 for the Treatment of COVID-19. (clinicaltrials.gov)
    P1, N=36, Suspended, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Suspended
    Trial suspension
    6ms
    START-POAF: Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial (clinicaltrials.gov)
    P3, N=400, Recruiting, Population Health Research Institute | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    6ms
    Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    HVTN143: Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants (clinicaltrials.gov)
    P1, N=77, Suspended, HIV Vaccine Trials Network | Not yet recruiting --> Suspended
    Trial suspension
    7ms
    AAA: Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study (clinicaltrials.gov)
    P4, N=42, Recruiting, University of Calgary | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    7ms
    Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery (clinicaltrials.gov)
    P3, N=184, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Surgery
    8ms
    Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 (clinicaltrials.gov)
    P1, N=144, Recruiting, Vir Biotechnology, Inc. | Trial completion date: Mar 2024 --> Apr 2027 | Trial primary completion date: Sep 2023 --> Sep 2026
    Trial completion date • Trial primary completion date • Combination therapy
    8ms
    MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care (clinicaltrials.gov)
    P3, N=200, Recruiting, Sunnybrook Health Sciences Centre | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Oct 2023 --> Oct 2025
    Trial completion date • Trial primary completion date
    8ms
    SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. (clinicaltrials.gov)
    P2, N=124, Recruiting, Vir Biotechnology, Inc. | Trial completion date: Oct 2026 --> Aug 2029 | Trial primary completion date: Oct 2026 --> Aug 2029
    Trial completion date • Trial primary completion date • Combination therapy
    8ms
    Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone (clinicaltrials.gov)
    P1, N=63, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    9ms
    Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, OHSU Knight Cancer Institute | Initiation date: Jan 2024 --> May 2024
    Trial initiation date
    9ms
    Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance (clinicaltrials.gov)
    P1/2, N=60, Recruiting, PENTA Foundation | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy
    9ms
    Amiodarone inhibits the Toll-like receptor 3-mediated nuclear factor κB signaling pathway by blocking organelle acidification. (PubMed, Biochem Biophys Res Commun)
    Amiodarone diminished the fluorescent dots of LysoTracker® Red DND-99 scattered over the cytoplasm of HUVEC. Therefore, the present study revealed that amiodarone selectively inhibited the TLR3-mediated NF-κB signaling pathway by blocking the acidification of intracellular organelles.
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • ICAM1 (Intercellular adhesion molecule 1) • TLR3 (Toll Like Receptor 3) • TERC (Telomerase RNA Component) • VCAM1 (Vascular Cell Adhesion Molecule 1)
    9ms
    Microfluidic production of amiodarone loaded nanoparticles and application in drug repositioning in ovarian cancer. (PubMed, Sci Rep)
    Moreover, stability over time of particles was evaluated. In vitro tests confirmed the efficacy of the drug delivery systems.
    Journal
    |
    CPT1A (Carnitine Palmitoyltransferase 1A)
    9ms
    Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION] (clinicaltrials.gov)
    P2, N=15, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting
    Enrollment open